ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0727

Prospective Cellular Biomarkers in ANCA Associated Vasculitis: A Pilot Study

Jakub Videman1, Adela Skoumalova1, Marketa Dudkova1, Martina Skacelova1, Anna Petrackova2, Zuzana Mikulkova2, Eva Kriegova3 and Pavel Horak1, 13rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic, 2Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia, Olomouc, Olomoucky kraj, Czech Republic, 3Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia, Olomouc, Czech Republic

Meeting: ACR Convergence 2024

Keywords: ANCA, ANCA associated vasculitis, Biomarkers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Significant progress has been achieved over the course of recent time in elucidating the complex underlying pathophysiological mechanisms of ANCA associated vasculitis (AAV). Despite these breakthroughs in research, the range of laboratory parameters available for evaluation in everyday clinical practice to guide the diagnostic process and management of patients with AAV remains very limited. Much effort is nowadays being expended on identifying such prospective biomarkers and assessing their potential for clinical application.

Methods: A panel of immune cell (sub)populations was investigated in peripheral blood samples from patients with newly confirmed diagnosis of AAV (n=52) and healthy controls (n=16). Patients with AAV were evaluated based on their initial clinical presentation using the validated Birmingham Vasculitis Activity Index version 3 (BVAS v3). For further analysis, patients were divided into subgroups based on overall disease severity (two groups defined as less severe and more severe by group median BVAS v3 score of 15), presence of particular organ domain involvement, and presence of identified disease relapse later on in the course of the condition requiring treatment reevaluation. Smaller subgroups significant by their clinical severity, namely patients requiring long-term hemodialysis due to AAV-conditioned organ damage (n=6) and patients with lethal course of disease (n=5), were also evaluated. Statistical analysis tools (Mann-Whitney, Spearman correlation, regression analysis) were used to evaluate data obtained.

Results: Preliminary analysis reveals significant differences between immune cell populations between studied groups and subgroups – among them non-specific upregulation of peripheral neutrophil granulocytes (p=9.28 ×10-8) and suppression of peripheral lymphocytes (p=2.6×10-8) and monocytes (p=2.06×10-6) in AAV patients compared to healthy controls. Similarly, particular immune cell subpopulations of CD 69+ NK cells (p=3.99 ×10-5) and CD 69+ CD 8+ T-lymphocytes (p=0.008) were highly expressed in AAV patients, whereas subpopulation of nonclassical monocytes was significantly reduced in AAV patients in comparison to healthy controls (p=2.81 ×10-7). These trends were also consistently observed in the comparison between subgroups defined by disease severity as described above, with patients presenting with more severe form of disease having further significantly elevated both CD 69+ NK cells and CD 69+ CD8 + T-lymphocytes (p=0.025, p=0.029) compared to patients with less severe AAV.

Conclusion: Significant flow cytometry immune cell profile differences can be observed between groups of patients with diagnosed AAV in comparison to healthy controls, as well as between subgroups of patients based on disease severity and organ involvement. Further inquiry into these differences is warranted, as they may offer potential for clinical application in precising diagnosis, assessing disease severity and possibly guiding treatment choices or even present possible therapeutic targets.

Supporting image 1

Supporting image 2


Disclosures: J. Videman: None; A. Skoumalova: None; M. Dudkova: None; M. Skacelova: None; A. Petrackova: None; Z. Mikulkova: None; E. Kriegova: None; P. Horak: None.

To cite this abstract in AMA style:

Videman J, Skoumalova A, Dudkova M, Skacelova M, Petrackova A, Mikulkova Z, Kriegova E, Horak P. Prospective Cellular Biomarkers in ANCA Associated Vasculitis: A Pilot Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/prospective-cellular-biomarkers-in-anca-associated-vasculitis-a-pilot-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prospective-cellular-biomarkers-in-anca-associated-vasculitis-a-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology